Med BioGene Inc.

Med BioGene Inc.

September 15, 2010 08:30 ET

Med BioGene's LungExpress Dx Technology the Focus of a Publication in the Journal of Clinical Oncology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 15, 2010) - Med BioGene Inc. (TSX VENTURE:MBI) today announced the publication of a study detailing the development and validation of the 15-gene signature used by LungExpress Dx entitled "Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer". The study was published online ahead of print in the prominent Journal of Clinical Oncology with an accompanying editorial.

LungExpess Dx is a genomic test under development to improve upon current staging by identifying those patients with early-stage non-small-cell lung cancer, who, following surgical removal of their tumor, are at a higher and lower risk of mortality. In the now published study of patient tumor specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, patients classified by the 15-gene signature as higher risk significantly benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit, and may have experienced a detrimental effect, from adjuvant chemotherapy. 

"We believe that the results described in the Journal of Clinical Oncology paper, along with the results of a subsequent validation study presented in January of 2010 at the joint meeting of the American Association for Cancer Research and International Association for the Study of Lung Cancer, establish that the use of LungExpress Dx will result in better-informed and personalized treatment decisions and improve the selection of patients who may benefit from adjuvant chemotherapy," stated Erinn B. Broshko, Chief Executive Officer of MBI.

Drs. Yang Xie and John D. Minna of the Hamon Center for Therapeutic Oncology Research and Simmons Cancer Center, University of Texas Southwestern Medical Center commented in the accompanying editorial that ". . . the tumor biomarker information [from the 15-gene signature] benefited patients in several ways: for patients whose tumors showed a good prognosis, it not only suggested that the patients did not need ACT [adjuvant chemotherapy], but that it might in fact be harmful. For patients with tumors with poor prognoses, the tumor biomarker information suggested that they needed additional therapy, and that they were likely to gain survival benefit from ACT. Thus, ACT would be worth the treatment toxicity for these patients."

The publication ( and editorial ( can be accessed online at the Journal of Clinical Oncology.

The study was led by MBI's collaborators, Drs. Ming-Sound Tsao, Frances A. Shepherd and Igor Jurisica, at the University Health Network, Princess Margaret Hospital in Toronto. Other centers involved in the study included: University of Toronto; National Cancer Institute of Canada Clinical Trials Group and Queen's University; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute; Broad Institute of Massachusetts Institute of Technology; Harvard University; Cleveland Clinic; and the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit

Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements include, but are not limited to, that with respect to the timing, completion and/or results of clinical trials or studies, future profits, future product revenues, future operations and plans, the completion and use of proceeds from financings and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

LungExpress Dx is MBI's trademark. Each trademark, trade name or service mark of any other entity appearing in this news release belongs to its holder.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information